Tempus AI Inc. (NASDAQ: TEM) announced that 37 abstracts have been accepted for presentation at the 2026 American Society of Clinical Oncology Annual Meeting, scheduled for May 29 through June 3, 2026 in Chicago.

The presentations will cover research on AI-driven approaches in precision medicine, including studies on histopathology review, biomarker testing, and genomic sequencing applications in cancer treatment. Notable research includes an AI-augmented histopathology review study examining next-generation sequencing success rates and an AI-driven RNA-based algorithm for predicting platinum response in metastatic pancreatic cancer.

Additional studies address mutation dynamics in breast cancer patients, treatment comparisons for thyroid cancer, and whole genome sequencing applications for myelodysplastic syndrome. The research also includes a multi-center prospective study evaluating an AI-enabled clinical decision support tool for early-stage non-small cell lung cancer biomarker testing.

Kate Sasser, chief scientific officer at Tempus, stated that the accepted research represents the company's largest collection of accepted research to date at the ASCO meeting. The studies examine the application of multimodal data and AI-driven insights in oncology precision medicine.

Tempus operates as a technology company focused on artificial intelligence applications in healthcare, maintaining a library of multimodal data for precision medicine solutions. The company provides AI-enabled tools to physicians for personalized patient care and therapeutic development.

The information is based on a company press release statement.